Aktis Oncology (NASDAQ:AKTS) Stock Has Average Price Target of $35.62 According to Analysts

Shares of Aktis Oncology (NASDAQ:AKTS) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $35.62.

Several equities research analysts have issued reports on AKTS shares. Oppenheimer initiated coverage on shares of Aktis Oncology in a research note on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price objective for the company. Weiss Ratings lowered shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, October 2nd. BMO Capital Markets began coverage on shares of Aktis Oncology in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 target price on the stock. Wall Street Zen lowered shares of Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Finally, Wedbush reaffirmed an “outperform” rating and set a $35.00 price target on shares of Aktis Oncology in a research report on Friday, October 2nd.

Institutional Investors Weigh In On Aktis Oncology

Several hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP purchased a new stake in shares of Aktis Oncology during the second quarter valued at approximately $63,372,000. Jupiter Topco LLC purchased a new position in shares of Aktis Oncology in the second quarter valued at $42,359,000. Alyeska Investment Group L.P. purchased a new position in shares of Aktis Oncology in the second quarter valued at $9,347,000. Blue Owl Capital Holdings LP increased its stake in Aktis Oncology by 8.9% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 3,343,827 shares of the technology company’s stock worth $65,104,000 after buying an additional 273,608 shares during the period. Finally, BlackRock Inc. increased its stake in Aktis Oncology by 7.9% during the 2nd quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company’s stock worth $73,431,000 after buying an additional 166,231 shares during the period. 28.84% of the stock is currently owned by hedge funds and other institutional investors.

Aktis Oncology Stock Performance

Shares of NASDAQ:AKTS traded up $0.34 during trading on Friday, reaching $16.62. 244,544 shares of the stock were exchanged, compared to its average volume of 347,615. Aktis Oncology has a 12-month low of $13.96 and a 12-month high of $34.19. The firm has a market cap of $893.33 million and a price-to-earnings ratio of -20.27. The firm’s 50-day moving average price is $18.54 and its 200 day moving average price is $20.79.

Aktis Oncology (NASDAQ:AKTS) last posted its earnings results on Thursday, November 12th. The technology company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.07). The company had revenue of $3.91 million for the quarter, compared to analysts’ expectations of $4.87 million. As a group, equities research analysts forecast that Aktis Oncology will post -1.84 EPS for the current year.

Aktis Oncology Company Profile

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.